Rituximab for autoimmune haemophilia: a proposed treatment algorithm (Q36014987)

11 August 2017

1 reference

title

Rituximab for autoimmune haemophilia: a proposed treatment algorithm (English)

1 reference

11 August 2017

0 references

1 reference

A Aggarwal

1

1 reference

11 August 2017

R Grewal

2

1 reference

11 August 2017

R J Green

3

1 reference

11 August 2017

L Boggio

4

1 reference

11 August 2017

D Green

5

1 reference

11 August 2017

B B Weksler

6

1 reference

11 August 2017

A Wiestner

7

1 reference

11 August 2017

G P Schechter

8

1 reference

11 August 2017

publication date

1 January 2005

1 reference

11 August 2017

1 reference

11 August 2017

volume

11

1 reference

11 August 2017

issue

1

1 reference

11 August 2017

page(s)

13-19

1 reference

Acquired haemophilia: review and meta-analysis focused on therapy and prognostic factors.

11 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111/J.1365-2516.2005.01060.X

Acquired hemophilia: a single-center survey with emphasis on immunotherapy and treatment-related side-effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2516.2005.01060.X

New products for managing inhibitors to coagulation factors: a focus on recombinant factor VIIa concentrate

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2516.2005.01060.X

Combination immunosuppressive therapy after factor VIII infusion for acquired factor VIII inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2516.2005.01060.X

Successful Treatment of Acquired Hemophilia with Oral Immunosuppressive Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2516.2005.01060.X

Efficacy of 2-chlorodeoxyadenosine in refractory factor VIII inhibitors in persons without hemophilia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2516.2005.01060.X

The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2516.2005.01060.X

Rituximab in the treatment of acquired factor VIII inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2516.2005.01060.X

Chemoattractants MDC and TARC are secreted by malignant B-cell precursors following CD40 ligation and support the migration of leukemia-specific T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2516.2005.01060.X

Treatment of refractory autoimmune (acquired) haemophilia with anti-CD20 (rituximab).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2516.2005.01060.X

Life-threatening bleeding from refractory acquired FVIII inhibitor successfully treated with rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2516.2005.01060.X

Selective B-cell depletion with rituximab for the treatment of patients with acquired hemophilia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2516.2005.01060.X

Acquired high-titer factor VIII inhibitor: fatal bleeding despite multimodal treatment including rituximab preceded by multiple plasmaphereses

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2516.2005.01060.X

10.1111/J.1365-2516.2005.01060.X

21 January 2018

Identifiers

DOI

1 reference

11 August 2017

1 reference